4 results match your criteria: "Molecular Recognition and Technological Development Institute[Affiliation]"
Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Basic Clin Pharmacol Toxicol
July 2018
Pharmacy and Pharmaceutical Technology, University of Valencia, Valencia, Spain.
Article Synopsis
- A study evaluated the link between glucocerebrosidase enzyme activity and clinical response in Gaucher disease type I patients undergoing enzyme replacement therapy (ERT) to help personalize treatment dosages.
- The researchers measured enzyme activity at two points: shortly after ERT infusion and during the infusion to assess how well the drug was working in the body.
- Findings indicated that enzyme activity levels were good predictors of clinical response, suggesting that monitoring these markers could enhance treatment effectiveness for Gaucher disease patients.
Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Cancer Chemother Pharmacol
January 2017
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, 46100, Burjassot, Valencia, Spain.
Purpose: Lenalidomide disease-specific toxicity profiles and potentially life-threatening adverse events support the consideration of diversity in starting doses. The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in multiple myeloma patients to identify and evaluate non-studied covariates that could be used for dose individualization.
Methods: Blood samples were collected from 15 multiple myeloma patients.
Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.
Clin Pharmacokinet
September 2016
Pharmacy Service, Hospital Universitario Dr. Peset, Avenida Gaspar Aguilar, 90, 46017, Valencia, Spain.
Background: Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase or velaglucerase for GD1, and set out to assess the process of enzymatic uptake by peripheral leukocytes.
Methods: A prospective semi-experimental study was conducted.
A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies.
J Lab Autom
December 2016
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Molecular Recognition and Technological Development Institute, Centro Mixto Universidad Politécnica de Valencia-Universidad de Valencia, Valencia, Spain.
A wide linearity range analytical method for the determination of lenalidomide in patients with multiple myeloma for pharmacokinetic studies is required. Plasma samples were ultrasonicated for protein precipitation. A solid-phase extraction was performed.
View Article and Find Full Text PDF